{"schema_version":"secwatch.filing_event.v1","accession":"0001437749-24-006743","form_type":"8-K","ticker":"VXRT","cik":"0000072444","company_name":"Vaxart, Inc.","filed_at":"2024-03-06T23:59:59+00:00","discovered_at":"2026-05-14T18:03:26.763410+00:00","generated_at":"2026-06-05T03:12:31.398354+00:00","sec_items":["5.02","8.01","9.01"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Vaxart appoints Steven Lo as CEO and President; Finney remains Chair","bullets":["Steven Lo appointed CEO, President, and director effective March 18, 2024.","Michael Finney steps down as interim CEO but continues as Board Chair.","Lo receives base salary of $600,000/year and target bonus of 50% of salary.","Equity awards: option for 1,000,000 shares (4-year vest) and RSU for 250,000 shares (4-year vest).","Lo brings 25+ years biopharma experience, most recently CEO at Valitor."],"urls":{"canonical":"https://secwatch.observer/filing/0001437749-24-006743","json":"https://secwatch.observer/filing/0001437749-24-006743.json","markdown":"https://secwatch.observer/filing/0001437749-24-006743.md","text":"https://secwatch.observer/filing/0001437749-24-006743.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/72444/000143774924006743/0001437749-24-006743-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/72444/000143774924006743/vxrt20240305c_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-05T03:12:31.398354+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"4ab3d3d328","claim":"Michael J. Finney changed role as Interim President and Chief Executive Officer at Vaxart, Inc..","evidence_excerpt":"In connection with Mr. Lo’s appointment, Michael J. Finney, Ph.D. will step down as the Company’s Interim President and Chief Executive Officer and principal executive officer on the Start Date; however, Dr. Finney will continue to serve as Chair of the Board.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/72444/000143774924006743/0001437749-24-006743-index.htm","confidence":1.0,"family_label":"Executive change","details":[{"label":"Action","value":"stepped down"},{"label":"Role","value":"Interim President and Chief Executive Officer"}],"fact_type":"executive_change"},{"claim_id":"5e4f9766db","claim":"Steven Lo was appointed as Chief Executive Officer, President, and director at Vaxart, Inc..","evidence_excerpt":"On March 4, 2024, the Board of Directors (the “Board”) of Vaxart, Inc. (the “Company”) appointed Steven Lo as the Company’s Chief Executive Officer, President, and principal executive officer, as well as a member of the Board, in each case effective as of March 18, 2024 (the “Start Date”).","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/72444/000143774924006743/0001437749-24-006743-index.htm","confidence":1.0,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Chief Executive Officer, President, and director"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}